全文获取类型
收费全文 | 2360篇 |
免费 | 99篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 40篇 |
妇产科学 | 15篇 |
基础医学 | 186篇 |
口腔科学 | 41篇 |
临床医学 | 195篇 |
内科学 | 324篇 |
皮肤病学 | 6篇 |
神经病学 | 134篇 |
特种医学 | 1005篇 |
外科学 | 183篇 |
综合类 | 28篇 |
一般理论 | 2篇 |
预防医学 | 111篇 |
眼科学 | 22篇 |
药学 | 80篇 |
中国医学 | 3篇 |
肿瘤学 | 97篇 |
出版年
2022年 | 5篇 |
2019年 | 22篇 |
2018年 | 22篇 |
2017年 | 13篇 |
2016年 | 30篇 |
2015年 | 35篇 |
2014年 | 52篇 |
2013年 | 97篇 |
2012年 | 105篇 |
2011年 | 104篇 |
2010年 | 107篇 |
2009年 | 84篇 |
2008年 | 110篇 |
2007年 | 163篇 |
2006年 | 123篇 |
2005年 | 101篇 |
2004年 | 106篇 |
2003年 | 68篇 |
2002年 | 104篇 |
2001年 | 82篇 |
2000年 | 93篇 |
1999年 | 102篇 |
1998年 | 73篇 |
1997年 | 59篇 |
1996年 | 56篇 |
1995年 | 36篇 |
1994年 | 41篇 |
1993年 | 26篇 |
1992年 | 21篇 |
1991年 | 17篇 |
1990年 | 23篇 |
1989年 | 42篇 |
1988年 | 44篇 |
1987年 | 36篇 |
1986年 | 50篇 |
1985年 | 35篇 |
1984年 | 26篇 |
1983年 | 21篇 |
1982年 | 24篇 |
1981年 | 12篇 |
1980年 | 8篇 |
1979年 | 11篇 |
1978年 | 9篇 |
1977年 | 6篇 |
1976年 | 5篇 |
1975年 | 8篇 |
1973年 | 6篇 |
1972年 | 5篇 |
1968年 | 6篇 |
1966年 | 5篇 |
排序方式: 共有2480条查询结果,搜索用时 15 毫秒
61.
Bickert T Wohlleben G Brinkman M Trujillo-Vargas CM Ruehland C Reiser CO Hess J Erb KJ 《Medical microbiology and immunology》2007,196(1):31-39
We analysed the effects of murine polyomavirus-like particles (PLPs) on bone marrow-derived dendritic cells (BMDCs) and T cells in vitro. BMDCs activated with PLPs up-regulated CD40, CD80, CD86 and major histocompatibility complex (MHC) class II surface markers and produced proinflammatory cytokines. Chimeric PLPs [expressing the ovalbumin (OVA)-peptides OVA(257-264) or OVA(323-339)], but not wildtype PLPs, activated OVA-specific CD8 T cells and OVA-specific CD4 T cells, respectively, indicating both MHC class I and II presentation of the peptides by antigen-presenting cells. Our results suggest that PLPs may be used as vaccine adjuvants priming dendritic cells to induce potent T cell responses. 相似文献
62.
63.
Trauma und Berufskrankheit - Ziel der Konsensuskonferenz war es, den aktuellen Wissensstand zur Indikationsstellung Bild gebender Verfahren in der Unfallchirurgie für die Regionen Hand, Knie... 相似文献
64.
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL 总被引:23,自引:6,他引:23 下载免费PDF全文
Pfreundschuh M Trümper L Kloess M Schmits R Feller AC Rübe C Rudolph C Reiser M Hossfeld DK Eimermacher H Hasenclever D Schmitz N Loeffler M;German High-Grade Non-Hodgkin's Lymphoma Study Group 《Blood》2004,104(3):634-641
Cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21), is standard chemotherapy for aggressive lymphomas. To determine whether biweekly CHOP (CHOP-14) with or without etoposide is more effective than CHOP-21, 689 patients ages 61 to 75 years were randomized to 6 cycles of CHOP-21, CHOP-14, CHOEP-21 (CHOP plus etoposide 100 mg/m2 days 1-3), or CHOEP-14. Patients in the 2-weekly regimens received granulocyte colony-stimulating factor (G-CSF) starting from day 4. Patients received radiotherapy (36 Gy) to sites of initial bulky disease and extranodal disease. Complete remission rates were 60.1% (CHOP-21), 70.0% (CHOEP-21), 76.1% (CHOP-14), and 71.6% (CHOEP-14). Five-year event-free and overall survival rates were 32.5% and 40.6%, respectively, for CHOP-21 and 43.8% and 53.3%, respectively, for CHOP-14. In a multivariate analysis, the relative risk reduction was 0.66 (P =.003) for event-free and 0.58 (P <.001) for overall survival after CHOP-14 compared with CHOP-21. Toxicity of CHOP-14 and CHOP-21 was similar, but CHOEP-21 and in particular CHOEP-14 were more toxic. Due to its favorable efficacy and toxicity profile, CHOP-14 should be considered the new standard chemotherapy regimen for patients ages 60 or older with aggressive lymphoma. 相似文献
65.
Perturbations in the erythroid marrow progenitor cell pools may play a role in the augmentation of HbF by 5-azacytidine 总被引:7,自引:2,他引:7
Torrealba-de Ron AT; Papayannopoulou T; Knapp MS; Fu MF; Knitter G; Stamatoyannopoulos G 《Blood》1984,63(1):201-210
In vivo observations on the kinetics of F cells and of fetal hemoglobin (HbF) synthesis and in vitro studies of erythroid progenitors, their number, and the gamma-gene expression in their progeny were carried out in baboons (Papio cynocephalus) treated with 5-azacytidine. Maximum effect on the increase of HbF production in vivo was observed only when an expanded erythroid marrow population was present. In these animals, as well as in normal animals, treatment resulted in a significant reduction of the late erythroid progenitor cell pools (erythroid clusters and erythroid colony-forming units, CFU-E) in the marrow. This reduction was more pronounced among those progenitors grown in the absence of added erythropoietin, and it was followed by a rebound a few days after treatment cessation, reflecting the accumulation of regenerating progenitors. An early increase in the in vitro synthesis of HbF in erythroid clusters and CFU-E colonies was observed. This increase was further documented at the cellular level, with immunofluorescent labeling of colonies with monoclonal anti-gamma- globin chain antibodies. In contrast to the findings in late progenitors, the number of erythroid burst-forming unit (BFU-E) colonies and the synthesis of HbF in these colonies was not influenced significantly by 5-azacytidine treatment. It is proposed that the toxic effects of 5-azacytidine on late progenitors, leading to faster mobilization of earlier progenitors to the next more mature compartment, play a role in the in vivo augmentation of HbF synthesis by this drug. This perturbation in the progenitor cell population kinetics and the presumed hypomethylation of the surviving differentiating cells may act synergistically to produce a maximum HbF response after 5-azacytidine treatment. 相似文献
66.
Ames P Studdert CA Reiser RH Parkinson JS 《Proceedings of the National Academy of Sciences of the United States of America》2002,99(10):7060-7065
Chemoreceptors of the methyl-accepting chemotaxis protein family form clusters, typically at the cell pole(s), in both Bacteria and Archaea. To elucidate the architecture and signaling role of receptor clusters, we investigated interactions between the serine (Tsr) and aspartate (Tar) chemoreceptors in Escherichia coli by constructing Tsr mutations at the six hydrophobic and five polar residues implicated in "trimer of dimers" formation. Tsr mutants with proline replacements could not mediate serine chemotaxis, receptor clustering, or clockwise flagellar rotation. Alanine and tryptophan mutants, although also nonchemotactic, formed receptor clusters, and some produced clockwise flagellar rotation, indicating receptor-coupled activation of the signaling CheA kinase. The alanine and tryptophan mutants evidently assemble defective receptor complexes that cannot modulate CheA activity in response to serine stimuli. In cells containing wild-type Tar receptors, tryptophan replacements in Tsr interfered with Tar function, whereas four Tsr mutants with alanine replacements regained Tsr function. These epistatic and rescuable phenotypes imply interactions between Tsr and Tar dimers in higher-order signaling teams. The bulky side chain in tryptophan mutants may prevent stimulus-induced conformational changes in the team, whereas the small side chain in alanine mutants may permit signaling control when teamed with functional receptor molecules. Direct physical interactions between Tsr and Tar molecules were observed by in vivo chemical crosslinking. Wild-type Tsr crosslinked to Tar, whereas a clustering-defective proline replacement mutant did not. These findings indicate that bacterial chemoreceptor clusters are comprised of signaling teams, seemingly based on trimers of dimers, that can contain different receptor types acting collaboratively. 相似文献
67.
Zwick C Birkmann J Peter N Bodenstein H Fuchs R Hänel M Reiser M Hensel M Clemens M Zeynalova S Ziepert M Pfreundschuh M;German High-Grade Non-Hodgkins Lymphoma Study Group 《Annals of hematology》2008,87(9):717-726
To compare toxicity of etoposide bolus with continuous infusion and to assess the efficacy of the CEMP (cisplatinum, etoposide, mitoxantrone, prednisone) regimen, 47 patients with refractory or relapsed aggressive non-Hodgkin's lymphoma older than 60 years (n=43) or not qualifying for high-dose chemotherapy (n=4) received five four-weekly CEMP cycles. Patients were randomised to start with bolus or continuous-infusion etoposide and then received bolus and infusional etoposide in an alternating fashion. The primary objective was the comparison of differences in the course of leukocytopenia and thrombocytopenia between the two application schedules. CEMP was well tolerated with little organ and moderate haematotoxicity. There was no difference in toxicity between bolus and continuous-infusion etoposide. Complete remission rate was 44% in patients relapsing >or=1 year, 27% in patients relapsing within the first year after achieving complete remission and 5% in primary refractory patients. Median event-free and overall survivals for all patients were 3 and 10 months, respectively. The observed equitoxicity and the more challenging logistics of a 60-h infusion make bolus injection the preferred application of etoposide. As the CEMP regimen is well tolerated and efficacious in elderly patients with relapsed or refractory aggressive non-Hodgkin's lymphoma for whom more aggressive therapies are not feasible, a three-weekly modification of CEMP should be tested in combination with rituximab. 相似文献
68.
69.
Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors 总被引:2,自引:6,他引:2
Piacibello W; Fubini L; Sanavio F; Brizzi MF; Severino A; Garetto L; Stacchini A; Pegoraro L; Aglietta M 《Blood》1995,86(11):4105-4114
A novel hematopoietic growth factor for primitive hematopoietic progenitor cells, the ligand for the flt3/flk2 receptor, (FL), has been recently purified and its gene has been cloned. In the present study, we investigated the effects of FL on the proliferation and differentiation of normal and leukemic myeloid progenitor cells. We demonstrate that FL is a potent stimulator of the in vitro growth of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin- 3 (IL-3), or G-CSF-dependent granulocyte-macrophage committed precursors from Lin- CD34+ bone marrow cells of normal donors. By contrast, FL does not affect the growth of erythroid-committed progenitors even in the presence of erythropoietin. The effect of FL on the proliferation and on the in vitro growth of clonogenic leukemic precursor cells was studied in 54 acute myeloid leukemia (AML) cases. Fresh leukemia blasts from 36 of 45 patients with AML significantly responded to FL without any relation to the French-American-British (FAB) subtype. FL stimulated the proliferation of leukemic blasts in a dose-dependent fashion. Synergistic activities were seen when FL was combined with G-CSF, GM-CSF, IL-3, or stem cell factor (SCF). FL as a single factor induced or increased significantly colony formation by clonogenic precursor cells from 21 of 24 patients with AML. In the presence of suboptimal and optimal concentrations of G-CSF, GM-CSF, IL3, SCF, or a combination of all factors, FL strongly enhanced the number of leukemic colonies (up to 18-fold). We also evaluated the induction of tyrosine phosphorylated protein on FL stimulation in fresh AML cells. We demonstrate that, on FL stimulation, a band of phosphorylated protein(s) of about 90 kD can be detected in FL- responsive, but not in FL-unresponsive cases. This study suggests that FL may be an important factor for the growth of myeloid leukemia cells, either as a direct stimulus or as a synergistic factor with other cytokines. 相似文献
70.
H Reiser E T Yeh C F Gramm B Benacerraf K L Rock 《Proceedings of the National Academy of Sciences of the United States of America》1986,83(9):2954-2958
Recently we described two murine T-cell membrane proteins, TAP (T-cell-activating protein) and TAPa (TAP-associated protein). Previous experiments suggested that TAP is involved in physiologic T-cell activation. The subject of this report is a genetic analysis of these molecules. TAP and TAPa map to the Ly-6 locus. The relationship of these molecules to other antigens encoded in this locus is examined. Based on tissue distribution, molecular structure, and functional properties, TAP is distinct from any previously described Ly-6 antigen, whereas TAPa is probably identical to the 34-11-3 antigen. TAP and TAPa are coexpressed on all cell types examined so far. Moreover, comparative studies demonstrate a complex developmentally regulated pattern in the expression of molecules encoded in this locus. 相似文献